See more : Libas Consumer Products Limited (LIBAS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Ra Medical Systems, Inc. (RMED) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ra Medical Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Southport Acquisition Corporation WT (PORT-WT) Income Statement Analysis – Financial Results
- Concordia Maritime AB (publ) (CCOR-B.ST) Income Statement Analysis – Financial Results
- Longchen Paper & Packaging Co., Ltd. (1909.TW) Income Statement Analysis – Financial Results
- Obrascón Huarte Lain, S.A. (OHLA.MC) Income Statement Analysis – Financial Results
- Zimmer Energy Transition Acquisition Corp. (ZT) Income Statement Analysis – Financial Results
Ra Medical Systems, Inc. (RMED)
About Ra Medical Systems, Inc.
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 2.23M | 0.00 | 0.00 | 0.00 | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 0.00 | 0.00 |
| Operating Expenses | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 8.77M | 1.57M | 2.37M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -18.20M | -29.27M | -36.06M | -57.73M | -31.16M | -17.54M | -4.10M |
| EBITDA Ratio | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 3.00K | 2.01M | 21.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -26.87M | -27.26M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -191,892.86% | -123,913.64% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
Ra Medical Systems Provides Enrollment Update for its Pivotal Atherectomy Clinical Trial
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in enrollment in its pivotal clinical trial to evaluate the safety and...
Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report first quarter 2021 financial results after market close on Tuesday, May 11, 2021. Ra Medical management will hold an investment community conference call that day at...
Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report first quarter 2021 financial results after market close on Tuesday, May 11, 2021. Ra Medical management will hold an investment community conference call that day at...
Glancy Prongay & Murray LLP Obtains Important Ruling for Ra Medical Systems, Inc. Investors in Securities Fraud Class Action
LOS ANGELES, April 14, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, announces that on March 24, 2021, the Honorable Larry Alan Burns of the United States District Court for the Southern...
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q1 2021 Results - Earnings Call Transcript
Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q1 2021 Results - Earnings Call Transcript
Ra Medical Systems Reports 2020 Fourth Quarter and Full Year Financial Results
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and 12 months ended December 31, 2020 and provides...
Ra Medical Systems to Participate in Upcoming Virtual Investment Conferences
CARLSBAD, Calif.--(BUSINESS WIRE)---- $RMED #RothConference--Ra Medical Systems to participate in the Virtual 33rd Annual Roth Conference and Maxim Emerging Growth Conference in March.
2 Falling Knives to Catch
Wall Street recommends purchasing shares of Ra Medical Systems Inc (RMED) and Baudax Bio Inc (NASDAQ:BXRX), which sounds quite unexpected since these two equities have shown poor performance over the prior 52 weeks through March 9. With positive recommendations despite...
Ra Medical Systems to Report 2020 Fourth Quarter and Full Year Financial Results on March 16, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra Medical management will hold an...
Source: https://incomestatements.info
Category: Stock Reports